Clearbridge Health Limited Announces Disposal of Subsidiaries: Key Details and Investor Impact

Clearbridge Health Limited has announced a significant corporate development that may be of interest to shareholders and investors. The Group has completed the sale of its dental business, specifically Clearbridge Lifestyle Pte Ltd (“CLS”) and its subsidiaries, through its 80.2%-owned subsidiary, Clearbridge Medical Group Pte. Ltd. (“CMG”). This transaction was finalized on May 4, 2026 and represents the full divestment of CLS, a loss-making asset, to Seow Kok Siam, Joseph, an existing shareholder and director within related entities. Below are the critical details and implications of this disposal.

1. Transaction Structure and Parties Involved

• Seller: Clearbridge Medical Group Pte. Ltd. (CMG, 80.2%-owned subsidiary of Clearbridge Health)
• Buyer: Seow Kok Siam, Joseph, holds 0.08% in Clearbridge Health, and 49% in Clearbridge Dental Holdings Pte. Ltd. He is not connected to the directors, executive officers or controlling shareholders of Clearbridge Health.
• Asset Sold: 3,983,948 issued and paid-up ordinary shares in Clearbridge Lifestyle Pte Ltd (“CLS”), representing 100% ownership.
• Completion: Disposal completed on May 4, 2026.

2. Business Description and Subsidiary Structure

• CLS Business: Management consultancy services for healthcare organisations, holding the Group’s dental business (7 operational dental clinics in Singapore).
• Subsidiary Ownership: CLS owns 51% of Clearbridge Dental Holdings Pte. Ltd., which in turn owns multiple dental clinics and entities (Dental Town, LKDS branches, Urban Dental, Dental Focus, Dentalfamily, etc.). Two entities are dormant, so 7 clinics are operational.
• Post-Transaction: CMG and Clearbridge Health will cease to have any interest in CLS and its subsidiaries.

3. Financial Terms and Consideration

• Consideration: S\$700,000, payable in seven equal instalments of S\$100,000 monthly. The first instalment was paid upon completion.
• Security: Buyer has granted a charge over the Sale Shares to CMG, released upon full payment.
• Internal Restructuring: Prior to disposal, S\$3,185,000 in loans from CMG to CLS were capitalized as ordinary shares, primarily for the acquisition of dental entities.

4. Financial Impact and Loss

• Loss on Disposal: The Group expects a loss of approximately S\$966,000 from this transaction.
• CLS Group Financials:
  • Adjusted net tangible liabilities as at Dec 31, 2025: S\$153,000
  • Adjusted net book value as at Dec 31, 2025: S\$1,666,000
  • Net loss for FY2025 attributable to Clearbridge: S\$3,245,000
• Rationale: Disposal allows Clearbridge to streamline operations, improve cost efficiency, and focus on core businesses. Proceeds will be used as working capital.

5. Financial Effects on Group

• NTA (Net Tangible Assets) per Share:
  • Before Disposal: S\$0.03 per share
  • After Disposal: S\$0.04 per share
• Earnings Per Share (EPS):
  • Before Disposal: (S\$0.30)
  • After Disposal: (S\$0.25)
• Relative Figures (Catalist Rule 1006):
  • Net asset value of assets disposed: 31.81% of Group NAV
  • Net loss attributable to assets disposed: (24.98)% of Group net loss
  • Consideration vs. market cap: 9.59%

  The transaction falls under “discloseable transaction” as per SGX Catalist Rules.

6. Shareholder and Director Interests

• No directors or controlling shareholders, other than via their shareholding, have any direct or indirect interest in the disposal.
• No appointments to the Board or service contracts are connected to the disposal.

7. Potential Price Sensitivity and Investor Considerations

• This disposal removes a substantial loss-making segment from Clearbridge’s balance sheet, improving both NTA and EPS, which may be viewed positively by investors seeking operational focus and financial improvement.
• The Group’s future financial position is expected to benefit from lower losses and improved cost efficiency.
• Proceeds are earmarked for working capital usage, supporting core operations.
• The loss on disposal is substantial but may be offset by future operational improvements and cost savings.
• The transaction’s classification as “discloseable” under SGX rules signals its materiality and potential relevance to share price movement, as it alters the Group’s asset and earnings profile.

8. Additional Information

• The Sale and Purchase Agreement (SPA) is available for inspection at the company’s registered office for three months.

Conclusion

This disposal marks a strategic shift for Clearbridge Health, focusing on its core businesses and divesting loss-making assets. The immediate financial impact is a recognized loss, but the removal of a loss-heavy subsidiary enhances the Group’s net tangible assets and earnings per share. Investors should monitor developments, as this transaction could influence Clearbridge’s future profitability and share price, especially as the company signals a renewed focus on operational efficiency and shareholder value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisers before making any investment decisions. The information is based on company announcements and may be subject to change or further clarification.

View Clearbridge Historical chart here